What now? ... we wait. And root like heck for the NUT Carcinoma trial to keep adding great data and numbers. And glean what we can from the Zenith AGM.

As a significant RVX shareholder, and very small Zenith shareholder, Im just glad to hear it is still all about ABL in the long term strategy. Hoping to get a small pop out of Zenith at some point, but Zenith sure appears to be the only engine to ignite ABL forward again. And that is going to take some time, most likely. 

jmho and glta